Antonia S, et al. Overall survival with durvalumab versus placebo after chemoradiotherapy in stage III NSCLC: updated results from PACIFIC. IASLC 2018, abstract PL02.01.
Betere behandeling van prostaatkanker door combinatie van bestralingstechnieken
feb 2017 | Radiotherapie, Uro-oncologie